AU2018393119B2 - Methods of treatment of hypertriglyceridemia - Google Patents

Methods of treatment of hypertriglyceridemia Download PDF

Info

Publication number
AU2018393119B2
AU2018393119B2 AU2018393119A AU2018393119A AU2018393119B2 AU 2018393119 B2 AU2018393119 B2 AU 2018393119B2 AU 2018393119 A AU2018393119 A AU 2018393119A AU 2018393119 A AU2018393119 A AU 2018393119A AU 2018393119 B2 AU2018393119 B2 AU 2018393119B2
Authority
AU
Australia
Prior art keywords
patient
week
pemafibrate
hdl
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018393119A
Other languages
English (en)
Other versions
AU2018393119A1 (en
Inventor
Gary Gordon
Ryu Oshima
Kazuhito SUEHIRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of AU2018393119A1 publication Critical patent/AU2018393119A1/en
Application granted granted Critical
Publication of AU2018393119B2 publication Critical patent/AU2018393119B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018393119A 2017-12-21 2018-12-20 Methods of treatment of hypertriglyceridemia Active AU2018393119B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609048P 2017-12-21 2017-12-21
US62/609,048 2017-12-21
PCT/US2018/066976 WO2019126597A1 (en) 2017-12-21 2018-12-20 Methods of treatment of hypertrigl yceridemia

Publications (2)

Publication Number Publication Date
AU2018393119A1 AU2018393119A1 (en) 2020-07-23
AU2018393119B2 true AU2018393119B2 (en) 2022-08-25

Family

ID=66995099

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018393119A Active AU2018393119B2 (en) 2017-12-21 2018-12-20 Methods of treatment of hypertriglyceridemia

Country Status (9)

Country Link
US (1) US20190224169A1 (enExample)
EP (1) EP3727376A4 (enExample)
JP (2) JP2021506907A (enExample)
CN (1) CN111741753A (enExample)
AU (1) AU2018393119B2 (enExample)
CA (1) CA3085951C (enExample)
MY (1) MY205171A (enExample)
SG (1) SG11202005850VA (enExample)
WO (1) WO2019126597A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202408500A (zh) * 2022-07-15 2024-03-01 日商興和股份有限公司 血中ｌｄｌ膽固醇降低劑
WO2024167964A1 (en) * 2023-02-08 2024-08-15 Kowa Company, Ltd. Methods of treating and preventing peripheral artery disease
WO2025069226A1 (ja) * 2023-09-26 2025-04-03 興和株式会社 ペマフィブラートを含有する医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535749C (en) * 2003-09-03 2011-11-01 Kowa Co., Ltd. Ppar activating compound and pharmaceutical composition containing same
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
KR102098032B1 (ko) * 2012-09-27 2020-04-07 교와 가부시키가이샤 지질 이상증 치료제
HK1231380A1 (zh) * 2014-06-26 2017-12-22 Cymabay Therapeutics, Inc. 严重高甘油三酯血症的治疗
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
DK3275438T3 (da) * 2016-07-29 2021-01-18 Kowa Co Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISHIBASHI SHUN; YAMASHITA SHIZUYA; ARAI HIDENORI; ARAKI EIICHI; YOKOTE KOUTARO; SUGANAMI HIDEKI; FRUCHART JEAN-CHARLES; KODAMA TAT: "Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial", ATHEROSCLEROSIS, ELSEVIER, AMSTERDAM, NL, vol. 249, 26 February 2016 (2016-02-26), AMSTERDAM, NL , pages 36 - 43, XP029542969, ISSN: 0021-9150, DOI: 10.1016/j.atherosclerosis.2016.02.029 *

Also Published As

Publication number Publication date
MY205171A (en) 2024-10-04
SG11202005850VA (en) 2020-07-29
WO2019126597A1 (en) 2019-06-27
EP3727376A4 (en) 2021-07-21
CA3085951A1 (en) 2019-06-27
JP2021506907A (ja) 2021-02-22
AU2018393119A1 (en) 2020-07-23
CN111741753A (zh) 2020-10-02
JP2023181451A (ja) 2023-12-21
CA3085951C (en) 2022-10-11
EP3727376A1 (en) 2020-10-28
US20190224169A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
US20210069158A1 (en) Methods of Preventing Occurrence of Cardiovascular Events
Yokote et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study)
Pu et al. Protective effects of sulforaphane on cognitive impairments and AD-like lesions in diabetic mice are associated with the upregulation of Nrf2 transcription activity
JP2023181451A (ja) 高トリグリセライド血症の治療方法
De Truchis et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study
Friedland et al. The cardiovascular effects of peroxisome proliferator-activated receptor agonists
JP2018536710A (ja) 混合型脂質異常症の治療
US11446282B2 (en) Methods of treating mixed dyslipidemia and hypertriglycertdemia
Bays et al. Icosabutate for the treatment of very high triglycerides: a placebo-controlled, randomized, double-blind, 12-week clinical trial
Baszczuk et al. The impact of supplementation with folic acid on homocysteine concentration and selected lipoprotein parameters in patients with primary hypertension
Wei et al. Betel nut chewing associated with increased risk of arterial stiffness
Chen et al. Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study
TWI741379B (zh) 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合
Stefanutti et al. Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol
Zeni Klafke et al. Biomarkers of subclinical atherosclerosis and natural products as complementary alternative medicine
Aguilar-Salinas et al. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study
US20230092776A1 (en) Methods of treating mixed dyslipidemia and hypertriglyceridemia
Roy et al. Significant reduction of elevated triglycerides and liver fibrosis in diabetic dyslipidemia with saroglitazar: A case report
Basuny et al. Evaluating the Safety and Efficacy of the traditional use of Turmeric powder as Antihypertensive in Elderly
Sharma et al. Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia–A Review
Yoon et al. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia
Insull Jr et al. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia
US20200360331A1 (en) COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES
Tonstad et al. The dual peroxisome proliferator–activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin
Okunevich Short report of original clinical trial of neurotropic drug: L-dopa efficiency of using in therapy of coronary artery disease

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS OF TREATMENT OF HYPERTRIGLYCERIDEMIA

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ OSHIMA, RYU; SUEHIRA, KAZUHITO AND GORDON, GARY

FGA Letters patent sealed or granted (standard patent)